Inhouse product
Indications
Motigut is indicated
in-
Dyspeptic symptom complex,
often associated with delayed gastric emptying, gastroesophageal reflux and
esophagitis:
Acute
nausea and vomiting of the
functional, organic, infectious, dietetic origin or induced by radiotherapy or
drug therapy or induced in migraine.
Parkinson's disease: In dopamine-agonist
induced nausea and vomiting.
Radiological studies: Speeding barium
transit in follow-through radiological studies.
* রেজিস্টার্ড চিকিৎসকের পরামর্শ মোতাবেক ঔষধ সেবন করুন'
Pharmacology
Domperidone is a
dopamine antagonist that principally blocks the dopamine receptors located in
the ChemoreceptorTrigger Zone (CTZ) and stomach. Its gastroprokinetic action is
based on its blocking effect of dopamine receptors that have an influence on the
motility of the gastrointestinal tract. Due to its weak penetration across the
blood-brain barrier, Domperidone has almost no effect on the dopaminergic
receptors in the brain, therefore, excluding psychotropic and neurologic side
effects. Domperidone restores normal motility and tone of the upper
gastrointestinal tract, facilitates gastric emptying, enhances antral and
duodenal peristalsis and regulates contraction of the pylorus. Domperidone also
increases esophageal peristalsis and lower esophageal sphincter pressure, and
thus prevents regurgitation of gastric content.
Dosage & Administration
Domperidone should be
taken 15-30 minutes before meals and, if necessary, before retiring.
The usual recommended oral dose of Domperidone is as follows:
In dyspeptic symptom:
In acute and sub-acute
conditions (mainly in acute nausea and vomiting):
By rectum in
suppositories:
* রেজিস্টার্ড চিকিৎসকের পরামর্শ মোতাবেক ঔষধ সেবন করুন'
Interaction
Concomitant
administration of anticholinergic drugs may antagonise the antidyspeptic
effect of domperidone: Antacids and antisecretory drugs should not be
given simultaneously with domperidone as they lower its oral bioavailability.
The main metabolic pathway of domperidone is through CYP3A4. In vitro data
suggest that the concomitant use of drugs that significantly inhibit this
enzyme may result in increased plasma levels of domperidone. Examples of
CYP3A4 inhibitors include: azole antifungals, macrolide antibiotics. HIV
protease inhibitors, nefazodone, etc. Theoretically, since domperidone
has gastro-kinetic effects it could influence the absorption of
concomitantly orally administered drugs, particularly those with sustained
release or enteric coated formulations. However, in patients already
stabilised on digoxin or paracetamol, concomitant administration
of domperidone did not influence the blood levels of these drugs.
Contraindications
Domperidone is
contraindicated to patients having known hypersensitivity to this drug and in
the case of neonates. Domperidone should not be used whenever gastrointestinal
stimulation might be dangerous i.e., gastrointestinal hemorrhage, mechanical
obstruction or perforation. Also contraindicated in patients with prolactin releasing
pituitary tumor (prolactinoma).
Side Effects
Side-effects are rare;
exceptionally some transient intestinal cramps have been reported.
Extrapyramidal phenomena are rare in young children and exceptional in adults:
they reverse spontaneously and completely as soon as the treatment is
stopped. As the pituitary gland is located outside the blood-brain
barrier, domperidone may induce an increase in the plasma prolactin level.
In rare case this hyperprolactinaemia may give rise to neuroendocrinological phenomena
such as galactorrhoea and gynaecomastia. When the blood-brain barrier is
immature (as in infants) or impaired, the possible occurrence of
neurological side-effects cannot be totally excluded. Rare allergic
reactions, such as rash and urticaria, have also been reported.
Pregnancy & Lactation
Domperidone given to
animals at doses up to 160 mg/kg/day did not produce teratogenic effects.
However, as most medicines, domperidone should only be used during the
first trimester of pregnancy if this is justified by the anticipated
therapeutic benefit. Up to now, there has been no evidence of any increase
in the risk of malformations in humans. The drug is excreted in breast
milk of lactating rats. In women, domperidone concentrations in breast
milk is 4 times lower than corresponding plasma concentrations. It is not known
whether this is harmful to the newborn. Therefore nursing is not
recommended for mothers who are taking domperidone, unless the expected
benefits outweigh any potential risk. Effects on ability to drive and use
machines: Domperidone does not affect the mental alertness.
Precautions & Warnings
Motigut should be used
with absolute caution in the case of children because there may be an increased
risk of extra-pyramidal reactions in young children because of an incompletely
developed blood-brain barrier. Since domperidone is highly metabolized in
liver, it should be used with caution in patient with hepatic impairment.
Use in Special Populations
Use in infants:
Because the metabolic and blood-brain barrier functions are not fully developed
during the first months of life, any drug should only be given to infants with
great caution and under close medical supervision. Since the typical absence of
neurological side effects with domperidone is mainly due to its poor
penetration through the blood-brain barrier, the possible occurrence of such
effects cannot be totally excluded in infants under 1 year of age. Use in liver
disorders: Since domperidone is highly metabolised in the liver, domperidone
should be used with caution in patients with hepatic impairment. Use in kidney
disorders: In patients with severe renal insufficiency (serum creatinine >6
mg/100ml, i.e. >O.6 mmol/I) the elimination half-life of domperidone as
increased from 7.4 to 20.8 hours, but plasma drug levels were lower than in
healthy volunteers. Since very little unchanged drug is excreted via the
kidneys, it is unlikely that the dose of a single acute administration needs to
be adjusted in patients with renal insufficiency. However, on repeated
administration, the dosing frequency should be reduced to once or twice daily,
depending on the severity of the impairment, and the dose may need to be
reduced. Generally, patients on prolonged therapy should be reviewed regularly.
Overdose Effects
Symptoms of overdosage
may include drowsiness, disorientation and extrapyramidal reactions, especially
in children. In case of overdosage, the administration of activated charcoal,
and close observation of the patients are recommended. Anticholinergic,
antiparkinson drugs or antihistamines with anticholinergic properties may be
helpful in controlling the extrapyramidal reactions.
Therapeutic Class
Motility Stimulants,
Motility stimulants/Dopamine antagonist, Prokinetic drugs
Storage Conditions
Store below 30°C,
Protected from light & moisture. Keep out of children's reach.
Chemical Structure
|
Molecular Formula : |
C22H24ClN5O2 |
|
Chemical Structure : |
Common Questions about Motigut 5 mg/5 ml
Suspension
What is Motigut 5 mg/5 ml Suspension used for?
Motigut 5 mg/5 ml
Suspension is a dopamine antagonist medication which is used to treat nausea
and vomiting.
Quick Tips
* রেজিস্টার্ড চিকিৎসকের পরামর্শ মোতাবেক ঔষধ সেবন করুন'
Login Or Registerto submit your questions to seller
No none asked to seller yet